Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases

FEBS Journal

Volumn 278, Issue 9, 2011, Pages 1444-1457

  Esposito, Francesca ^a   Kharlamova, Tatyana ^a   Distinto, Simona ^b   Zinzula, Luca ^a   Cheng, Yung Chi ^c   Dutschman, Ginger ^c   Floris, Giovanni ^a   Markt, Patrick ^d   Corona, Angela ^a   Tramontano, Enzo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

anthraquinones; HIV 1 ribonuclease H; NNRTI resistant; RNase H; RT inhibitors

Indexed keywords

2,2 DICHLORO 12 (4 CHLOROPHENYL)DODECANOIC ACID; ALIZARIN; ALIZARINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; DELAVIRDINE; DNA POLYMERASE; EFAVIRENZ; EMODIN; ETRAVIRINE; K 126; K 45; K 49; K 52; K 53; K 54; K 56; K 57; K 61; KNA 26; KNA 53; MAGNESIUM ION; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIBONUCLEASE H; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; BINDING SITE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTHRAQUINONES; BASE SEQUENCE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTAGENESIS; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79955072485     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08057.x     Document Type: Article

References (49)

1. Mehellou Y, &, De Clercq E, (2010) Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 53, 521-538.
2. Hughes SH, Arnold E, &, Hostomsky Z, (1998) RNase H of retroviral reverse transcriptases. In Ribonucleases H (, Crouch RJ, &, Toulme JJ, eds), pp 195-224. Les Editions INSERM, Paris.
3. Klarmann GJ, Hawkins ME, &, Le Grice SF, (2002) Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target. AIDS Rev 4, 183-194. (Pubitemid 36104230)
4. Rice PA, &, Baker TA, (2001) Comparative architecture of transposase and integrase complexes. Nat Struct Biol 8, 302-307. (Pubitemid 32275012)
5. Tramontano E, (2006) HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target. Mini Rev Med Chem 6, 727-737. (Pubitemid 43881124)
6. Tramontano E, &, Di Santo R, (2010) HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development. Curr Med Chem 17, 2837-2853.
7. Singh R, Geetanjali R, &, Chauhan SMS, (2004) 9,10-Anthraquinones and other biologically active compounds from the genus Rubia. Chem Biodivers 1, 1241-1264.
8. Huang HS, Chiou JF, Fong Y, Hou CC, Lu YC, Wang JY, Shih JW, Pan YR, &, Lin JJ, (2003) Activation of human telomerase reverse transcriptase expression by some new symmetrical bis-substituted derivatives of the anthraquinone. J Med Chem 46, 3300-3307. (Pubitemid 36842414)
9. Tan JH, Zhang QX, Huang ZS, Chen Y, Wang XD, Gu LQ, &, Wu JY, (2006) Synthesis, DNA binding and cytotoxicity of new pyrazole emodin derivatives. Eur J Med Chem 41, 1041-1047. (Pubitemid 44353868)
10. Wheate NJ, Brodie CR, Collins JG, Kemp S, &, Aldrivch-Wright JR, (2007) DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis. Mini Rev Med Chem 6, 627-648. (Pubitemid 47099183)
11. Huang Q, Lu G, Shen HM, Chung MC, &, Onq CN, (2007) Anticancer properties of anthraquinones from rhubarb. Med Res Rev 27, 609-630.
12. Sill AD, Andrews ER, Sweet FW, Hoffman JW, Tiernan PL, Grisar JM, Fleming RW, &, Mayer GD, (1974) Bis-basic-substituted polycyclic aromatic compounds. A new class of antiviral agents. Bis-basic ethers of anthraquinone and bisalkamine esters of anthraquinonedicarboxylic acids. J Med Chem 17, 965-968.
13. Sydiskis RJ, Owen DG, Lohr JL, Rosler KHA, &, Blomster RN, (1991) Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrob Agents Chemother 35, 2463-2466.
14. Barnard DL, Huffman JH, Morris JLB, Wood SG, Hughes BG, &, Sidwell RW, (1992) Evaluation of antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cyromegalovirus. Antiviral Res 17, 63-77.
15. Bamard DL, Fairbaim DW, O'Neill KL, Gage TL, &, Sidwell RW, (1995) Anti-human cytomegalovirus activity and toxicity of sulfonated anthraquinones and anthraquinone derivatives. Antiviral Res 28, 317-329.
16. Semple SJ, Pyke SM, Reynolds GD, &, Flower FLP, (2001) In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus. Antiviral Res 49, 169-178. (Pubitemid 32322470)
17. Dang S, Zhang Z, Chen Y, Zhang X, Wang B, Yuan L, &, Cheng Y, (2006) Inhibition of the replication of hepatitis B virus in vitro by emodin. Med Sci Monit 12, 302-306.
18. Higuchi H, Mori K, Kato A, Ohkuma T, Endo T, Kaji H, &, Kaji A, (1991) Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase. Antiviral Res 15, 205-216.
19. Farnet CM, Wang B, Lipford JR, &, Bushman FD, (1996) Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc Natl Acad Sci USA 93, 9742-9747. (Pubitemid 26296679)
20. Kharlamova T, Esposito F, Zinzula L, Floris G, Cheng Y-C, Dutschman GE, &, Tramontano E, (2009) Inhibition of HIV-1 ribonuclease H activity by novel frangula-emodine derivatives. Med Chem 5, 398-410.
21. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, Danzeisen S, Olsen D, Carroll S, Embrey E, Wai J, et al. (2003) Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem 278, 2777-2780. (Pubitemid 36801178)
22. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, &, La Colla P, (2005) 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res 65, 117-124. (Pubitemid 40222288)
23. Himmel DM, Sarafianos SG, Dharmasena S, Hossain MM, McCoy-Simandle K, Ilina T, Clark AD, Knight JL, Julias JG, Clark PK, et al. (2006) HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol 1, 702-712.
24. Hang QL, Li Y, Yang Y, Cammack N, Mirzadegan T, &, Klumpp K, (2007) Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem Biophys Res Commun 352, 341-350. (Pubitemid 44838494)
25. Yonetani T, (1982) The Yonetani-Theorell graphical method for examining overlapping subsite of enzyme centers. Methods Enzymol 87, 500-509.
26. Shaw-Reid CA, Feuston B, Munshi V, Getty K, Jrueger J, Hazuda DJ, Parniak MA, Miller MD, &, Lewis D, (2005) Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry 44, 1595-1606. (Pubitemid 40204402)
27. Hang JQ, Rajendran S, Yang Y, Li Y, In PWK, Overton H, Parkes KEB, Cammack N, Martin JA, &, Klumpp K, (2004) Activity of the isolated HIV RNase H domain and specific inhibition by N-hydrosymides. Biochem Biophys Res Commun 317, 321-329. (Pubitemid 38452485)
28. Chung JY, Hah J-M, &, Cho AE, (2009) Correlation between performance of QM/MM docking and simple classification of binding sites. J Chem Inf Model 49, 2382-2387.
29. Sluis-Cremer N, Temiz NA, &, Bahar I, (2004) Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2, 323-332. (Pubitemid 39242962)
30. Pata JD, Stirtan WG, Goldstein SW, &, Steitz TA, (2004) Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 101, 10548-10553. (Pubitemid 38955779)
31. So HP, Yan Y, Prasad G, Smith RF, Daniels CL, Abeywickrema PD, Reid JC, Loughran HM, Kornienko M, Sharma S, et al. (2010) Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol 84, 7625-7633.
32. Palaniappan C, Fay PJ, &, Bambara RA, (1995) Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J Biol Chem 270, 4861-4869.
33. Palaniappan C, Wisniewski M, Jacques PS, Le Grice SF, Fay PJ, &, Bambara RA, (1997) Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. J Biol Chem 272, 11157-11164. (Pubitemid 27184110)
34. Rausch JW, Lener D, Miller JT, Julias JG, Hughes SH, &, Le Grice SF, (2002) Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochemistry 41, 4856-4865. (Pubitemid 34298652)
35. Julias JG, McWilliams MJ, Sarafianos SG, Arnold E, &, Hughes SH, (2002) Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc Natl Acad Sci USA 99, 9515-9520. (Pubitemid 34764645)
36. Julias JG, McWilliams MJ, Sarafianos SG, Alvord WG, Arnold E, &, Hughes SH, (2003) Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. J Virol 77, 8548-8554. (Pubitemid 36871483)
37. Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, Bambara RA, &, Demeter LM, (2000) Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 74, 8390-8401. (Pubitemid 30666690)
38. Archer RH, Wisniewski M, Bambara RA, &, Demeter LM, (2001) The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages. Biochemistry 40, 4087-4095. (Pubitemid 32280446)
39. Esposito F, Fanti V, Marzeddu R, Randaccio P, Tramontano E, &, Zinzula L, (2009) Validation of a computed radiography device to monitor the HIV-1 RNase H activity. Nucl Instrum Methods Phys Res 607, 226-228.
40. Tramontano E, &, Cheng Y-C, (1992) HIV-1 reverse transcriptase inhibition by dipyridodiazepinone derivative: BI-RG-587. Biochem Pharmacol 43, 1371.
41. Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR, &, Cheng Y-C, (1992) In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 41, 446-451.
42. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, &, Mainz DT, (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49, 6177-6196. (Pubitemid 44595196)
43. Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, Klepeis JL, Kolossvary I, Moraes MA, Sacerdoti FD, et al. (2006) Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, FL, USA, doi:.
44. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, &, Klein ML, (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79, 926-935.
45. Gibson DA, &, Carter EA, (1993) Time-reversible multiple time scale ab initio molecular dynamics. J Phys Chem 97, 13429.
46. Ryckaert JP, Ciccotti G, &, Berendsen HJC, (1977) Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23, 327-341.
47. Darden T, York D, &, Pedersen L, (1993) Particle mesh Ewald: an N.log(N) method for Ewald sums in large systems. J Chem Phys 98, 10089.
48. Humphrey W, Dalke A, &, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14, 27-38.
49. Wolber G, &, Langer T, (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45, 160.